A respiratory syncytial virus (RSV) vaccine has been a goal for researchers for a long time, given the serious outcomes of an RSV infection. According to the CDC, an RSV vaccine could dramatically reduce hospital and intensive-care admissions, especially for children and seniors.
A series of clinical trials tested a vaccine made from inactivated RSV in children in the 1960s. Unfortunately, the vaccine candidate worsened the disease in children when they were later naturally infected with RSV.
However, these new vaccines have shown good safety and effectiveness results in clinical trials. This article will review what RSV is and the list of vaccine candidates that are entering or are in phase 3 clinical trials.Read More »RSV vaccine candidates are entering phase 3 trials — stopping a dangerous disease